EcoDrugPlus

Ensembl ID : ENSCING00000011366
Gene Symbol: CI-IKK-ALPHA
2 Cross references
464 Possible Orthologues:

Ensembl ID : ENSCING00000009770
Gene Symbol: CI-ZF
2 Cross references
183 Possible Orthologues:

Ensembl ID : ENSCING00000003634
Gene Symbol: CI-FXR
2 Cross references
388 Possible Orthologues:

26s Proteasome Non-Atpase Regulatory Subunit 13-Like

Ensembl ID : ENSCING00000006810
Gene Symbol: LOC100184104
4 Cross references
228 Possible Orthologues:

26s Proteasome Non-Atpase Regulatory Subunit 14

Ensembl ID : ENSCING00000020086
Gene Symbol: LOC100179683
4 Cross references
215 Possible Orthologues:

26s Proteasome Non-Atpase Regulatory Subunit 6

Ensembl ID : ENSCING00000004450
Gene Symbol: LOC100184510
4 Cross references
214 Possible Orthologues:

26s Proteasome Regulatory Subunit 10b

Ensembl ID : ENSCING00000009539
Gene Symbol: LOC100187162
4 Cross references
250 Possible Orthologues:

26s Proteasome Regulatory Subunit 4

Ensembl ID : ENSCING00000003550
Gene Symbol: LOC100182082
4 Cross references
323 Possible Orthologues:

26s Proteasome Regulatory Subunit 6b

Ensembl ID : ENSCING00000003873
Gene Symbol: LOC100184190
4 Cross references
199 Possible Orthologues:

26s Proteasome Regulatory Subunit 7

Ensembl ID : ENSCING00000005748
Gene Symbol: LOC100185096
4 Cross references
234 Possible Orthologues:

3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 1-Like

Ensembl ID : ENSCING00000000832
Gene Symbol: LOC100176622
4 Cross references
266 Possible Orthologues:

4-Hydroxyphenylpyruvate Dioxygenase

Ensembl ID : ENSCING00000015215
Gene Symbol: LOC100185199
4 Cross references
276 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).